Subject primary prevention

In view of the perceived benefit of aspirin in the secondary prevention of stroke and myocardial infarction, two large trials involving physicians as subjects were initiated to study the effect of aspirin in the primary prevention of arterial thrombosis. In the American study, 22,000 volunteers (age 40 to 84 years) were randomly assigned to take 325 mg of aspirin every other day or placebo. The trial was halted early, after a mean follow-up of 5 years, when a 45% reduction in the incidence of myocardial infarction and a 72% reduction in the incidence of fatal myocardial infarction were noted with aspirin treatment. However, total mortality was reduced only 4% in the aspirin group, a difference that was not statistically significant, and there was a trend for a greater risk of hemorrhagic stroke with aspirin. Thus, the prophylactic use of aspirin in an apparently healthy population is not recommended at this time, unless there are risk factors for cardiovascular disease. 

The Lipid Research Clinics Coronary Primary Prevention Trial (L16, L17) is a landmark double-blind study in which cholestyramine, a bile acid se-questrant that is not absorbed from the gut, was used to lower plasma cholesterol. The investigators recruited 3806 men, with a Type II hyperlipoproteinemia phenotype and in good health, into the study. All were prescribed a cholesterol-lowering diet. Subjects were randomly assigned to a treatment group (who were prescribed 24 g cholestyramine daily) and a group with similar baseline characteristics who received an inactive placebo. A 19% lower incidence of coronary heart disease over a mean of 7.4 years in... 

More controversial is the extent to which primary prevention (treatment of clinically unaffected patients with moderate elevation of cholesterol levels) should include drugs, and whether secondary prevention should ever start with drugs rather than diet. Dietary treatment can lower cholesterol levels in committed subjects, and is obviously less costly than drug treatment. Unforhmately numerous studies have shown that over any substantial period of time (e.g. one year) diet has no clinically significant influence on plasma cholesterol and the wait for diet to have an effect often results in patients being lost from hospital follow-up after their initial myocardial infarction. Evidence comes from the WOSCOPS stud) in which pravastatin 40 mg/day and placebo were compared in 6590 men age 50-70 with LDL cholesterol 4-6 mmol/1 pravastatin reduced coronary heart disease (fatal and nonfatal events) by 31%. The authors estimated that treatment of 1000 such subjects each year would prevent 20 myocardial infarctions. Concerns that primary prevention could have a net adverse outcome (that cholesterol reduction increased the risk of cancer or violent deaths) have been laid to rest by a number of outcome trials. 

On the basis of findings from studies such as the MRFIT and the LRC-CPPT discussed previously, hypercholesterolemia in adults is now defined in terms of CHD risk. The National Institutes of Health ATP of the NCEP has issued its third report for the detection, evaluation, and treatment of hypercholesterolemia (ATP III). The ATP III built on earlier reports and expanded the indications for intensive cholesterol lowering. In ATP I, strategies for primary prevention of CHD in subjects with LDL-C >160mg/dL or 130 to 159mg/dL and multiple risk factors... 

Of the markers mentioned previously in this chapter, only hsCRP has fulfilled the required criteria for a novel marker of CHD risk, and national guideUnes for its measurement in the primary prevention of CHD have recently been issued jointly by the American Heart Association (AHA) and the CDC (AHAyCDC). Here we discuss the roles of hsCPR in CHD, the metabolic syndrome, diabetes, and hypertension, and its possible role in atherogenesis. We conclude with a discussion of possible preventive measures in those individuals with increased levels of hsCRP. A comprehensive review on this subject has been published. 

The increased production and use of yttrium in technical materials (see Section 28.3.1) might cause contamination of the human environment, and this should be the subject of interdisciplinary studies focused on primary prevention. Most importantly, the inhalation of yttrium compounds may be toxic and also possibly carcinogenic for humans. 

The PPP (Primary Prevention Project) study [15] was a randomized, controlled (no placebo), open trial investigating low-dose aspirin (100 mg daily) in 4,495 subjects (42.5% males) with one or more cardiovascular risk factors. Follow-up was 3.6 years. Aspirin was found to lower the frequency of all the end points, being statistically significant for cardiovascular death (relative risk 0.56), and total cardiovascular events (relative risk 0.77), with non-significant reduction in myocardial infarction (relative risk 0.69) and stroke (risk reduction 0.67). Seven hundred and forty-two diabetics (17%) were included in the study but no separate information on this subgroup is provided in the original publication. 

The American Heart Association Study Group, "Primary Prevention of the Atherosclerotic Diseases," chaired by J. Stamler and A. M. Lillenfeld, have reported on the magnitude of the prevention problem. This report is comprehensive in its background and recommendations and should be read by all who are interested in this aspect of the subject. A broad review of experimental cardiovascular disease has been compiled by Selye. ... 

Clinical studies investigated the antioxidative effects of antioxidant supplementation of humans on ex vivo LDL oxidation [48-52], We have shown that dietary supplementation of p-carotene of healthy subjects resulted in a moderate inhibitory effect on the susceptibility of LDL to oxidative modification [53-55] in some, but not in all studied subjects. The combination of carotenoids with vitamin E, in contrast, demonstrated a synergistic inhibitory effect on LDL oxidation in all studied cases [56], We showed that supplementation of vitamin E of atherosclerotic apolipoprotein E-deficient mice (25 pg/mouse/day for 3 months) inhibited LDL oxidation by 40% and the atherosclerotic lesion area by 35% [57], In humans, unlike in animal models, both vitamin E and carotenoids did not significantly reduce atherosclerosis in primary prevention trials [58], This result may be related to insufficient absorption, insufficient potency, and inappropriate tissue distribution,... 

Primary Prevention 4495 subjects with > 1 major a-tocopherol (synthetic) Vitamin E had no significant effect on Primary Prevention... 

Table 1 Summary of large mterventlon trials >1000 subjects) Investigating the role of antioxidants and CVD In primary prevention ...

Secondary prevention defined as subjects with documented cancer including nonmelanoma skin cancer (although some of the primary prevention trials did not exclude those with nonmelanoma skin cancer at baseline). 

An average of 4 years of supplementation with 400 lU of vitamin E per day was found to exert no beneficial or harmful effect on CVD outcomes or on nephropathy. The Primary Prevention Project trial found no effect of vitamin E (300mg/day) supplementation for 3 or 4 years in diabetic subjects, and the Heart Protection Study, which included a number of people with diabetes, also reported no benefit of a combination of antioxidant vitamins on mortality or incidence of vascular disease. 

Alkylation reactions are subject to the same constraints that affect all Sn2 reactions (Section 11.3). Thus, the leaving group X in the alkylating agent R—X can be chloride, bromide, iodide, or tosylate. The alkyl group R should be primary or methyl, and preferably should be allylic or benzylic. Secondary halides react poorly, and tertiary halides don t react at all because a competing E2 elimination of HX occurs instead. Vinylic and aryl halides are also unreactive because backside approach is sterically prevented. 

In most commercial processes, borax is obtained from lake brines, tincal and colemanite. The primary salt constituents of brine are sodium chloride, sodium sulfate, sodium carbonate and potassium chloride. The percent composition of borax as Na2B40 in brine is generally in the range 1.5 to 1.6%. Borax is separated from these salts by various physical and chemical processes. The brine solution (mixed with mother liquor) is subject to evaporation and crystahzation for the continuous removal of NaCl, Na2C03 and Na2S04, respectively. The hot liquor consists of concentrated solution of potassium salts and borate components of the brine. The insoluble solid particles are filtered out and the liquor is cooled rapidly in continuous vacuum crystallizers under controlled conditions of temperatures and concentrations to crystallize KCl. Cystallization of borax along with KCl from the concentrated liquor must not occur at this stage. KCl is separated from the hquor by filtration. Bicarbonate then is added to the liquor to prevent any formation of sodium... 

---